Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
Asianet Newsable on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
According to analyst H.C. Wainwright, the positive study result from Lilly materially de-risks Viking's (VKTX) oral VK2735 ...
Viking Therapeutics (VKTX) has been on a wild ride this year, with shares sliding over the past month even after a massive run in the past 3 years. So what is the market rethinking here? See our ...
Upstart biotech company Viking Therapeutics ( VKTX 3.98%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its ...
For those willing to take a chance, let's consider two biotech stocks that could eventually become solid, well-established drugmakers: CRISPR Therapeutics(NASDAQ: CRSP) and Viking Therapeutics(NASDAQ: ...
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...
Zacks Investment Research on MSN
Viking Therapeutics, Inc. (VKTX) registers a bigger fall than the market: Important facts to note
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.15, marking a -2.51% move from the previous day. This move lagged the S&P 500's daily loss of 0.16%. Meanwhile, the Dow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback